Processing

Please wait...

Settings

Settings

Goto Application

1. US20160089355 - COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

Claims

1. A method of reducing occurrence of a cardiovascular event in a hypercholesterolemia patient comprising,
identifying a patient having triglycerides (TG) of at least 150 mg/DL and HDL-C of less than 40 mg/dL in a blood sample taken from the patient as the only risk factor of a cardiovascular event, wherein the patient has not previously had a cardiovascular event, and administering ethyl icosapentate in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,
wherein the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, and salts thereof; and
wherein the patient has hypercholesterolemia.
2. The method according to claim 1, wherein said 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor is administered to the patient at least one of before, during and after administering the ethyl icosapentate.
3. The method according to claim 1, wherein the patient has at least one risk factor selected from the group consisting of obesity, hypertension, prehypertension, diabetes, prediabetes, and abnormal glucose tolerance.
4. The method according to claim 1, wherein the patient has at least two risk factors selected from the group consisting of obesity, hypertension, prehypertension, diabetes, prediabetes, and abnormal glucose tolerance.
5. The method according to claim 1, wherein the ethyl icosapentate is administered daily for two years or more.
6. The method according to claim 1, wherein the ethyl icosapentate is orally administered at a dose of 0.3 g/day to 6 g/day.
7. The method according to claim 6, wherein the ethyl icosapentate is orally administered at a dose of 1.8 g/day to 2.7 g/day.
8. The method according to claim 1, wherein the patient is a male patient.
9. The method according to claim 1, wherein the content of the ethyl icosapentate is at least 96.5% by weight in relation to the total content of fatty acid that is simultaneously administered with the ethyl icosapentate.
10. The method according to claim 2, wherein the ethyl icosapentate is in an amount of 600-900 mg per administration.
11. The method according to claim 9, wherein the ethyl icosapentate is in an amount of 600-900 mg per administration.